The U.S. FDA approved an expanded 26-week efficacy claim for Zimmer Biomet Holdings Inc.'s Gel-One Cross-linked Hyaluronate for the treatment of knee pain associated with osteoarthritis.
Discover more about S&P Global’s offerings
US FDA approves expanded efficacy claim for Zimmer's knee pain drug
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
The U.S. FDA approved an expanded 26-week efficacy claim for Zimmer Biomet Holdings Inc.'s Gel-One Cross-linked Hyaluronate for the treatment of knee pain associated with osteoarthritis.